

**Department of Dermatology, Venereology and Leprosy
Sree Balaji Medical College and Hospital, Chennai**

Journal discussion (03/02/2026)

**Title of journal: ROFLUMILAST IN DERMATOLOGY:
A NEWER**

PHOSPHODIESTERASE-4 INHIBITOR

Presented by: Dr Nourin Basheer (Junior Resident)

Abstract: Roflumilast is a potent and selective inhibitor of phosphodiesterase-4 inhibitor. It has already been in use for treating COPD exacerbations for a few years. In recent years, after the success of apremilast in the treatment of multiple inflammatory skin conditions, roflumilast has been tried in various clinical trials and got FDA approval in a topical formulation for the treatment of psoriasis and seborrheic dermatitis. There is a lack of options among non-steroidal topical formulations for treating inflammatory skin conditions; thus, attention has been turned towards a molecule such as roflumilast, which is the need of the hour. In this article, we will look at the various skin conditions where roflumilast is available as a treatment option.

Conclusion: Roflumilast is a newer drug with a favourable safety profile. It is a cost-effective drug when compared to other commonly used immunosuppressive agents such as cyclosporine and injectable methotrexate. The oral formulation is available in the Indian market, but the topical formulation is not yet available, which is a major limitation. Currently, roflumilast is FDA-approved only for psoriasis and seborrheic dermatitis, but it has a much wider potential to be used for the treatment of other dermatoses. Roflumilast in both topical and oral formulations will be a good armamentarium for a dermatologist in the near future.

Journal citation : Singh S, Paul D, Snehal A. Roflumilast in Dermatology: A Newer Phosphodiesterase-4 Inhibitor. Indian J Dermatol. 2025 Jan-Feb;70(1):38-41. doi: 10.4103/ijd.ijd_261_24. Epub 2024 Dec 30. PMID: 39896310; PMCID: PMC11784981.

Received: Dec 2024. **Accepted:** Feb, 2025

